We investigated lectin pathway cord blood concentrations in infants ... MBL, M-, L-, H-ficolin, MASP-2 and MASP-3 were measured in cord blood using EIA/TRIFMA. Multivariate logistic regression ...

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic ...

SEATTLE, WA, USA I March 21, 2025 I Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating ...

Zaltenibart (OMS906) is Omeros’ investigational inhibitor of MASP ... lectin-associated serine protease-3 (MASP-3), the key and most proximal activator of the complement system’s alternative ...